Cytokinetics, Incorporated (FRA:KK3A)

Market Cap	6.50B +21.0%
Revenue (ttm)	74.33M +2,609.3%
Net Income	-640.88M
EPS	-5.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	53.00
Previous Close	53.50
Day's Range	53.00 - 53.00
52-Week Range	26.20 - 63.00
Beta	n/a
RSI	47.47
Earnings Date	Feb 27, 2026

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 498
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KK3A

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Financial numbers in USD